Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Use of antivirals and antibiotics for COVID-19 in Mexico City: A Real-World Multicenter Cohort Study

View ORCID ProfileJavier Mancilla-Galindo, Jorge Óscar García-Méndez, View ORCID ProfileJessica Márquez-Sánchez, View ORCID ProfileRodrigo Estefano Reyes-Casarrubias, View ORCID ProfileEduardo Aguirre-Aguilar, View ORCID ProfileHéctor Isaac Rocha-González, View ORCID ProfileAshuin Kammar-García
doi: https://doi.org/10.1101/2020.10.13.20211797
Javier Mancilla-Galindo
1Unidad de Investigación UNAM-INC, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
2Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Javier Mancilla-Galindo
Jorge Óscar García-Méndez
2Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico
3Departamento de Posgrado y Educación Médica Continua, Instituto Nacional de Cancerología, Mexico City, Mexico
4Departamento de Infectología, Fundación Clínica Médica Sur, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Márquez-Sánchez
5Departamento de Infectología, Instituto Nacional de Pediatría, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jessica Márquez-Sánchez
Rodrigo Estefano Reyes-Casarrubias
2Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico
3Departamento de Posgrado y Educación Médica Continua, Instituto Nacional de Cancerología, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rodrigo Estefano Reyes-Casarrubias
Eduardo Aguirre-Aguilar
6Departamento de Atención Institucional Continua y Urgencias, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eduardo Aguirre-Aguilar
Héctor Isaac Rocha-González
7Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Héctor Isaac Rocha-González
Ashuin Kammar-García
6Departamento de Atención Institucional Continua y Urgencias, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
7Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ashuin Kammar-García
  • For correspondence: kammar_nutrition@hotmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

We aimed to characterize real-world use of antivirals and antibiotics in patients with COVID-19 and their associations with mortality. We conducted a real-world retrospective cohort study in 688 primary-to-tertiary medical units in Mexico City; 395,343 patients were evaluated for suspected COVID-19 between February 24 and September 14, 2020. All patients with a positive RT-PCR for SARS-CoV-2 (n=137,012) were included; those receiving unspecified antivirals (n=137), excluded, and groups of antivirals with <30 patients (n=20), eliminated. Survival and mortality risk analyses were done for patients receiving antivirals, antibiotics, both, or none (exposition groups). 136,855 patients were analyzed; mean age 44.2 (SD:16.8) years; 51.3% were men. 16.6% received an antiviral (3%), antibiotic (10%), or both (3.6%). More symptomatic patients received antivirals and antibiotics more often. Antivirals studied were Oseltamivir (n=8414), Amantadine (n=319), Lopinavir-Ritonavir (n=100), Rimantadine (n=61), Zanamivir (n=39), and Acyclovir (n=36). Survival with antivirals (73.7%, P<.001) and antibiotics (85.8%, P<.001) was lower than no antiviral/antibiotic (93.6%) in the general population. Increased risk of death was observed with antivirals in ambulatory (HR=4.7, 95%CI:3.94-5.62) and non-critical (HR=2.03, 95%CI:1.86-2.21) patients; no benefit in hospitalized and critical patients. Oseltamivir was associated with increased mortality in the general population (HR=1.72, 95%CI:1.61-1.84), ambulatory (HR=4.79, 95%CI:4.01-5.75), non-critical (HR=2.05, 95%CI:1.88-2.23), and pregnancy (HR=8.35, 95%CI:1.77-39.30). Antibiotics were a protective factor in hospitalized (HR=0.81, 95%CI:0.77-0.86) and critical patients (HR=0.67, 95%CI:0.63-0.72), but a risk factor in the general population (HR=1.13, 95%CI:1.08-1.19) and children and adolescents (HR=4.22, 95%CI:2.01-8.86). In conclusion, oseltamivir was associated with increased mortality or no benefit in all groups. Common antivirals for COVID-19 should be avoided. Antibiotics may increase survival in hospitalized and critical patients. Vaccination history and rapid differentiation of etiologic agent will be key to promptly initiate or avoid antivirals during the COVID-19-influenza season.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This is a retrospective study using an open-source dataset of patients receiving medical care for suspected COVID-19 in Mexico City. The Secretariat of Health of Mexico approved the collection and publication of data.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data Availability

Data are available upon reasonable request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 14, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Use of antivirals and antibiotics for COVID-19 in Mexico City: A Real-World Multicenter Cohort Study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Use of antivirals and antibiotics for COVID-19 in Mexico City: A Real-World Multicenter Cohort Study
Javier Mancilla-Galindo, Jorge Óscar García-Méndez, Jessica Márquez-Sánchez, Rodrigo Estefano Reyes-Casarrubias, Eduardo Aguirre-Aguilar, Héctor Isaac Rocha-González, Ashuin Kammar-García
medRxiv 2020.10.13.20211797; doi: https://doi.org/10.1101/2020.10.13.20211797
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Use of antivirals and antibiotics for COVID-19 in Mexico City: A Real-World Multicenter Cohort Study
Javier Mancilla-Galindo, Jorge Óscar García-Méndez, Jessica Márquez-Sánchez, Rodrigo Estefano Reyes-Casarrubias, Eduardo Aguirre-Aguilar, Héctor Isaac Rocha-González, Ashuin Kammar-García
medRxiv 2020.10.13.20211797; doi: https://doi.org/10.1101/2020.10.13.20211797

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8787)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1863)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (492)
  • Hematology (207)
  • HIV/AIDS (394)
  • Infectious Diseases (except HIV/AIDS) (10563)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1755)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (265)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1844)
  • Public and Global Health (3985)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)